Determinants of spironolactone binding specificity in the mineralocorticoid receptor

被引:23
作者
Rogerson, FM
Yao, YZ
Smith, BJ
Dimopoulos, N
Fuller, PJ
机构
[1] Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia
[2] Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia
关键词
D O I
10.1677/jme.0.0310573
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Spironolactone is a mineralocorticoid receptor (MR) antagonist in clinical use. The compound has a very low affinity for the glucocorticoid receptor (GR). Determinants of binding specificity of spironolactone to the MR were investigated using chimeras created between the ligand-binding domains (LBDs) of the MR and the GR. These chimeras had previously been used to investigate aldosterone binding specificity to the MR. Spironolactone was able to compete strongly for [(3)H]-aldosterone and [(3)H]-dexamethasone binding to a chimera containing amino acids 804-874 of the MR, and weakly for [(3)H]-dexamethasone binding to a chimera containing amino acids 672-803 of the MR. Amino acids 804-874 were also critical for aldosterone binding specificity. Models of the MR LBD bound to aldosterone and spironolactone were created based on the crystal structure of the progesterone receptor LBD. The ligand-binding pocket of the MR LBD model consisted of 23 amino acids and was predominantly hydrophobic in nature. Analysis of this model in light of the experimental data suggested that spironolactone binding specificity is not governed by amino acids in the ligand-binding pocket.
引用
收藏
页码:573 / 582
页数:10
相关论文
共 33 条
[1]   CLONING OF HUMAN MINERALOCORTICOID RECEPTOR COMPLEMENTARY-DNA - STRUCTURAL AND FUNCTIONAL KINSHIP WITH THE GLUCOCORTICOID RECEPTOR [J].
ARRIZA, JL ;
WEINBERGER, C ;
CERELLI, G ;
GLASER, TM ;
HANDELIN, BL ;
HOUSMAN, DE ;
EVANS, RM .
SCIENCE, 1987, 237 (4812) :268-275
[2]  
ARRIZA JL, 1991, COLLOQ INSE, V215, P13
[3]   A single amino acid mutation of Ala-773 in the mineralocorticoid receptor confers agonist properties to 11β-substituted spirolactones [J].
Auzou, G ;
Fagart, J ;
Souque, A ;
Hellal-Lévy, C ;
Wurtz, JM ;
Moras, D ;
Rafestin-Oblin, ME .
MOLECULAR PHARMACOLOGY, 2000, 58 (04) :684-691
[4]   Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition [J].
Bledsoe, RK ;
Montana, VG ;
Stanley, TB ;
Delves, CJ ;
Apolito, CJ ;
McKee, DD ;
Consler, TG ;
Parks, DJ ;
Stewart, EL ;
Willson, TM ;
Lambert, MH ;
Moore, JT ;
Pearce, KH ;
Xu, HE .
CELL, 2002, 110 (01) :93-105
[5]   MECHANISM OF THE ANTI-MINERALOCORTICOID EFFECTS OF SPIROLACTONES [J].
CORVOL, P ;
CLAIRE, M ;
OBLIN, ME ;
GEERING, K ;
ROSSIER, B .
KIDNEY INTERNATIONAL, 1981, 20 (01) :1-6
[6]   ANTIANDROGENIC EFFECT OF SPIROLACTONES - MECHANISM OF ACTION [J].
CORVOL, P ;
MICHAUD, A ;
MENARD, J ;
FREIFELD, M ;
MAHOUDEAU, J .
ENDOCRINOLOGY, 1975, 97 (01) :52-58
[7]   ALDOSTERONE ANTAGONISTS DESTABILIZE THE MINERALOCORTICOSTEROID RECEPTOR [J].
COUETTE, B ;
LOMBES, M ;
BAULIEU, EE ;
RAFESTINOBLIN, ME .
BIOCHEMICAL JOURNAL, 1992, 282 :697-702
[8]   SPIRONOLACTONE, AN ALDOSTERONE ANTAGONIST, ACTS AS AN ANTIGLUCOCORTICOSTEROID ON THE MOUSE MAMMARY-TUMOR VIRUS PROMOTER [J].
COUETTE, B ;
MARSAUD, V ;
BAULIEU, EE ;
RICHARDFOY, H ;
RAFESTINOBLIN, ME .
ENDOCRINOLOGY, 1992, 130 (01) :430-436
[9]   The spironolactone renaissance [J].
Doggrell, SA ;
Brown, L .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (05) :943-954
[10]   ACTIVATION OF THE RAT-KIDNEY MINERALOCORTICOID RECEPTOR [J].
EISEN, LP ;
HARMON, JM .
ENDOCRINOLOGY, 1986, 119 (04) :1419-1426